Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy
article
OA: closed
CC0
⤵ 22 in-corpus citations
AI-generated summary
This paper investigates the effects of gonadotropin-releasing hormone agonists combined with estrogen-progestogen replacement therapy on specific biological markers and outcomes.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Gonadotropin-releasing hormone agonists are effective in the treatment of endometriosis and myomas, both of which are estrogen-dependent processes, but there is a high clinical recurrence rate after therapy is discontinued. Long-term continuous therapy (2 years or more) has a cumulative effect on bone loss and causes other uncomfortable or harmful side effects. Noninvasive assessments of disease response in patients with myomas have shown that bone changes might be prevented and other side effects of long-term therapy can be alleviated by adding back small amounts of estrogen or progestin. No comparable data are available for patients with endometriosis because the need for repeated laparoscopy has made long-term studies impractical. Nevertheless, a short-term study of patients with endometriosis showed that adding small amounts of progestin during treatment with a gonadotropin-releasing hormone agonist may help prevent bone changes.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (8)
- Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis via openalex
- W1531102169 via openalex
- W1998117916 via openalex
- W2050557100 via openalex
- W2297593361 via openalex
- W2412142226 via openalex
- W2397186489 via openalex
- W4294307685 via openalex
Cited by (23)
- Minimising menopausal side effects whilst treating endometriosis and fibroids 2015
- Endometriosis 2012
- Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update 2012
- Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain 2006
- Gonadotropin Releasing Honnone Agonist and Antagonist for Endometriosis 2003
- Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome 2002
- HRT as add-back therapy 2002
- Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis 1999
- Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis 1997
- A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone 1997
- The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl) 1996
- Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain 1995
- Endometriosis: Current Management 1995
- Leuprorelin 1994
- An alternative to hysterectomy? GnRH analogue combined with hormone replacement therapy 1993
- Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin 1992
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone 1992
- The potential for the use of GnRH agonists for treatment of dysfunctional uterine bleeding 1992
- Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin 1992
- Hormone treatment of endometriosis: The estrogenthreshold hypothesis 1992
- Spontaneous and steroid-induced recurrence of endometriosis after suppression by a gonadotropin-releasing hormone antagonist in the rat 1991
- Goserelin 1991
- Nafarelin 1990
Source provenance
- europepmc
- last seen: 2026-09-18T06:10:57.818014+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:12:10.587122+00:00
License: CC0
· commercial use OK